SION — Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics, Inc. Common Stock (SION) is a biotechnology company listed on NASDAQ. It is led by Michael Cloonan M.B.A., based in 21 Hickory Drive, Waltham, MA, United States, 02451, with about 48 employees. Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Net income was -$20.3M.

Use this SION page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SION quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SION SEC filings page. Lician reads the product cache first so this HTML stays unique to Sionna Therapeutics, Inc. Common Stock even when a live quote feed is slow.